Levothyroxine (Synthroid) Pregnancy and Lactation Safety

Why Levothyroxine Is Essential During Pregnancy

Adequate maternal thyroid hormone is required for fetal brain development during the first 12 weeks of gestation, before the fetal thyroid gland begins producing its own T4. Levothyroxine, a synthetic form of thyroxine (T4), replaces the hormone that the thyroid gland cannot produce in sufficient quantities in hypothyroid women.

Untreated or undertreated maternal hypothyroidism carries measurable obstetric and developmental risks. A 2019 meta-analysis published in Thyroid (N=18,435 pregnancies) found that women with subclinical hypothyroidism had a 60% increased risk of pregnancy loss (RR 1.60, 95% CI 1.28 to 2.01) compared to euthyroid women [1]. The Controlled Antenatal Thyroid Screening (CATS) study (N=21,846) demonstrated that untreated hypothyroidism in pregnancy was associated with a 3.8-point reduction in offspring IQ at age 3 [2]. These findings anchor the clinical consensus: levothyroxine must not be discontinued when a patient becomes pregnant.

The 2017 ATA Guidelines for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum recommend that women already taking levothyroxine increase their dose by approximately 20% to 30% upon confirmation of pregnancy, ideally by week 4 to 6 of gestation [3]. A practical strategy cited in the guidelines: take two extra tablets per week of the current dose, which approximates a 29% increase.

How Levothyroxine Works

Levothyroxine sodium is a synthetic T4 molecule identical in structure to the endogenous hormone produced by the thyroid gland. After oral absorption (40% to 80% bioavailability depending on formulation and fasting state), T4 circulates bound to thyroxine-binding globulin (TBG), transthyretin, and albumin, with approximately 0.03% circulating as free T4.

Peripheral tissues convert T4 to the biologically active triiodothyronine (T3) via type 1 and type 2 deiodinase enzymes. T3 binds nuclear thyroid hormone receptors in virtually every tissue, regulating basal metabolic rate, cardiac output, bone turnover, and CNS myelination [4]. During pregnancy, TBG concentrations rise 2- to 3-fold under estrogen stimulation, increasing total T4 demand by 20% to 50%. This explains why pre-pregnancy levothyroxine doses become insufficient within weeks of conception.

The drug's long half-life of approximately 6 to 7 days means that missed single doses rarely cause acute symptoms, but chronic underdosing across weeks produces clinically significant hypothyroidism. That pharmacokinetic property also means dose adjustments take 4 to 6 weeks to reach new steady state, which is why the ATA mandates TSH retesting every 4 weeks during the first half of pregnancy [3].

Trimester-Specific TSH Targets and Dose Titration

The 2017 ATA guidelines replaced the old universal upper TSH cutoff of 2.5 mIU/L with a population-based approach: if trimester-specific reference ranges are available from the local laboratory, use them. If not, a reasonable upper limit is 4.0 mIU/L [3]. Many endocrinologists and maternal-fetal medicine specialists, including the Endocrine Society, still favor tighter control.

"For women on levothyroxine prior to pregnancy, the goal should be a TSH <2.5 mIU/L in the first trimester, with adjustment to trimester-specific ranges thereafter," states the 2012 Endocrine Society Clinical Practice Guideline authored by De Groot et al. [5].

First trimester demands are the most clinically urgent. HCG, which peaks between weeks 8 and 11, has weak TSH-receptor agonist activity that transiently suppresses TSH in euthyroid women. In hypothyroid women on fixed-dose levothyroxine, this hCG effect may mask the rising T4 requirement, making early dose escalation and frequent monitoring even more important.

A prospective study by Yassa et al. (N=60) showed that empirically increasing levothyroxine by two extra tablets per week at the time of a positive pregnancy test maintained TSH below 2.5 mIU/L in 85% of women through the first trimester, compared to only 46% of women who waited for a lab-confirmed TSH elevation before adjusting [6]. The message is clear. Don't wait for labs to drift.

HealthRX.com Trimester Dose-Adjustment Protocol

| Gestational Window | Action | TSH Recheck | |---|---|---| | Positive pregnancy test (weeks 4 to 6) | Increase dose by ~29% (two extra tablets/week) | 4 weeks after adjustment | | Weeks 8 to 12 | Recheck TSH; titrate if above trimester-specific range | Every 4 weeks | | Weeks 12 to 20 | Continue monitoring; dose often stabilizes | Every 4 weeks | | Weeks 20 to delivery | Maintain dose; recheck TSH once per trimester minimum | Every 4 to 8 weeks | | Immediately postpartum | Return to pre-pregnancy dose | 6 weeks postpartum |

Risks of Untreated Hypothyroidism in Pregnancy

The consequences of maternal hypothyroidism fall into two categories: obstetric complications and fetal neurodevelopmental harm. Both are dose-dependent, meaning worse thyroid control produces worse outcomes.

A large retrospective cohort study using U.S. Insurance claims data (N=115,746) published in Obstetrics & Gynecology found that women with overt hypothyroidism had adjusted odds ratios of 1.7 for preeclampsia, 1.6 for gestational diabetes, and 1.4 for preterm delivery compared to euthyroid controls [7]. Subclinical hypothyroidism (TSH 2.5 to 10 mIU/L with normal free T4) carried smaller but still statistically significant elevations in miscarriage and preterm birth risk [1].

On the neurodevelopmental side, the landmark Haddow et al. Study (1999) measured IQ scores in children born to women whose second-trimester TSH was above the 98th percentile. The mean IQ of their children was 7 points lower than matched controls, and 19% scored below 85 (vs. 5% of controls) [8]. This was among the first studies to shift clinical practice toward universal thyroid screening in pregnancy, though screening recommendations remain debated.

Placental abruption, stillbirth, and low birth weight have also been associated with untreated hypothyroidism in smaller studies, though confounding factors make precise risk quantification difficult. The weight of evidence supports one principle: the risk of treating with levothyroxine during pregnancy is near zero, while the risk of not treating is substantial and well-documented.

Safety Profile During Pregnancy

Levothyroxine has no known teratogenic effects. The drug replicates a hormone the body already produces, and the synthetic molecule is structurally identical to endogenous T4. The FDA removed the old pregnancy letter categories in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR), but the current Synthroid prescribing information explicitly states: "Levothyroxine should not be discontinued during pregnancy" [9].

Overtreatment (iatrogenic thyrotoxicosis) is the primary medication-related risk. Suppressed TSH (<0.1 mIU/L) with elevated free T4 in the first trimester has been associated with a modest increase in preterm delivery and low birth weight in some studies [10]. The goal is euthyroidism, not TSH suppression.

Drug interactions require attention during pregnancy. Prenatal vitamins containing iron or calcium can reduce levothyroxine absorption by 40% to 65% if taken simultaneously [4]. The standard recommendation is to separate levothyroxine from iron-containing prenatals by at least 4 hours. Women taking the liquid or soft-gel capsule formulations (Tirosint, Tirosint-SOL) may experience less absorption interference, though head-to-head pregnancy data are limited.

"Thyroid function tests should be checked in the first trimester in all women on levothyroxine, and the dose should be adjusted to maintain TSH within the trimester-specific reference range," the 2017 ATA guideline authors state [3].

Levothyroxine During Breastfeeding

Levothyroxine is excreted into human breast milk in small amounts. However, the quantities transferred are too low to produce any thyroid effect in the nursing infant. The relative infant dose (RID), the standard pharmacokinetic measure of drug transfer through breast milk, is well below the 10% threshold used to classify a medication as compatible with breastfeeding [11].

The American Academy of Pediatrics (AAP) has long classified levothyroxine as compatible with breastfeeding. LactMed, the NIH's Drugs and Lactation Database, states: "Maternal levothyroxine supplementation is unlikely to affect the nursing infant's thyroid status" [12]. No dose adjustment of levothyroxine is required specifically for breastfeeding.

An important clinical nuance: postpartum thyroiditis affects 5% to 10% of women and can cause transient thyrotoxicosis followed by hypothyroidism in the first 12 months after delivery [3]. Women already on levothyroxine should return to their pre-pregnancy dose immediately after delivery and have TSH rechecked at 6 weeks postpartum. New thyroid symptoms during breastfeeding (fatigue, weight changes, mood disturbance, hair loss) should prompt thyroid function testing rather than being attributed solely to sleep deprivation and the demands of new parenthood.

Women with Hashimoto's thyroiditis may experience a postpartum flare in thyroid autoimmunity due to the immune rebound that occurs after the relative immunosuppression of pregnancy. TSH can rise significantly in the months following delivery, sometimes requiring a temporary dose that exceeds even the elevated pregnancy dose.

Monitoring Protocol for Pregnant Women on Levothyroxine

The minimum monitoring schedule recommended by the ATA includes TSH measurement every 4 weeks during the first half of pregnancy (through week 20) and at least once between weeks 26 and 32 [3].

A complete monitoring panel typically includes:

• TSH: primary marker for dose adequacy
• Free T4: confirms whether TSH changes reflect actual hormone levels (assay interference from TBG elevation can occur with some immunoassay platforms)
• TPO antibodies: checked once, ideally preconception, to stratify risk of postpartum thyroiditis and progression of autoimmune thyroid disease

Women who are newly diagnosed with hypothyroidism during pregnancy (detected through screening or symptom-driven testing) should begin levothyroxine immediately. The starting dose depends on the degree of TSH elevation: overt hypothyroidism (TSH >10 mIU/L) typically warrants a full replacement dose of 1.6 mcg/kg/day, while subclinical hypothyroidism (TSH 4 to 10 mIU/L) may start at 50 to 75 mcg daily with rapid titration [3].

For women planning pregnancy who are already euthyroid on levothyroxine, preconception counseling should include the instruction to increase the dose proactively upon a positive home pregnancy test. This is a time-critical action. The fetal brain is developing before many women have their first prenatal visit.

Special Populations and Clinical Considerations

Women with thyroid cancer history: Patients on TSH-suppressive levothyroxine doses for differentiated thyroid cancer face a unique challenge during pregnancy. The degree of TSH suppression should be maintained per the oncologic risk stratification, but the pregnancy-related increase in TBG means doses often need to increase by 30% to 50%. Coordination between the oncologist and obstetrician is required [3].

IVF and assisted reproduction: Women undergoing in vitro fertilization (IVF) have higher rates of subclinical hypothyroidism, and some reproductive endocrinologists treat to a TSH target of <2.5 mIU/L before embryo transfer regardless of the population-based reference range. A 2018 meta-analysis in Human Reproduction Update (N=43,586 from 47 studies) found that levothyroxine treatment in women with subclinical hypothyroidism undergoing IVF reduced miscarriage rates (RR 0.62, 95% CI 0.48 to 0.82) [13].

Hyperemesis gravidarum: Severe nausea and vomiting in early pregnancy can impair oral levothyroxine absorption. If a patient cannot keep oral medications down for more than a week, intravenous levothyroxine (available in hospital settings) may be considered, though this scenario is uncommon. Liquid levothyroxine formulations may be better tolerated than tablets in milder cases of nausea.

Postpartum depression screening: Hypothyroidism and postpartum depression share overlapping symptoms (fatigue, cognitive slowing, depressed mood, difficulty concentrating). TSH should be checked before attributing these symptoms entirely to a psychiatric diagnosis, especially in women with known thyroid disease.

Preconception Planning

The ideal time to optimize thyroid function is before conception. The ATA recommends that women with known hypothyroidism achieve a TSH between 0.5 and 2.5 mIU/L before attempting pregnancy [3]. This buffer ensures that the inevitable rise in T4 demand during early pregnancy does not push TSH above goal before the first prenatal visit.

Women who discover they are pregnant before seeing a provider should increase their levothyroxine dose immediately by two tablets per week and schedule a TSH check within one to two weeks. Waiting for an appointment to "get permission" to adjust the dose risks weeks of suboptimal thyroid hormone levels during the most sensitive period of fetal neurodevelopment.

Switching levothyroxine brands or formulations during pregnancy is discouraged unless clinically necessary, because bioequivalence between products can vary by up to 12.5% under FDA standards [9]. A brand switch mid-pregnancy should be followed by TSH rechecking at 4 weeks.